『Research plan for the in vitro amplification batch process of immune cell preparations and their derivative application development』table（Plan number：PBIRB-2019， Joint Human Trials Committee Number：19-S-009-2）

Precision biotechnology is mainly aimed at improving the quality of human life and extending life. Combining Taiwan's high-quality research and medical environment, in addition to focusing on the development of immune cell preparations and their derivatives, as well as automated production processes, it is also used to enhance one's own immunity, assist and promote the treatment of cancer patients, and improve the quality of life during cancer treatment. The government actively opens up regulations on immune cell therapy in cancer treatment and meets the urgent needs of patients, The integration of medical treatment with cell therapy and related biotechnology in Taiwan will be the correct direction for the development of the big health industry.
Precision Biotechnology passed the Clinical Trial Review (IND) of the Taiwan Food and Drug Administration in October 2018 and conducted Phase I clinical trials. It has experience in conducting human clinical trials and optimizing cell preparation processes, as well as a team of oncologists. It provides high-quality cell products and treatment management and services, and manufactures our patented cell preparations in legally compliant GTP laboratories to meet clinical needs. The recruitment for this study was initiated by our R&D department, Specializing in process improvement and the combined treatment of anticancer drugs, developing immune cell cryopreservation technology, and collaborating with domestic and foreign biotechnology factories to develop more innovative technologies, providing prevention, treatment, and prognosis medicine, we will be able to provide more accurate personalized medical solutions.
The recruitment of this research case only requires donors to extract approximately 20 mL of peripheral blood and blood samples from compliant medical institutions, providing precise biotechnology for immune cell research, development, and application. In the future, the research and development results will be implemented in clinical trials to benefit cancer patients and clinical medical technology use.

1. Test name:

Research plan for the in vitro amplification batch process of immune cell preparations and their derivative application development

Investigate ex-vivo expansion of immune cell in batches process and  development of extending application

2. Name and address of testing institution:

Precision Biotechnology Co., Ltd./7th floor, No. 185, Section 4, Xinbei Avenue, Xinzhuang District, New Taipei City

3. Name and contact information of the test host:

Huang Yile/0932633137

4. Test purpose or overview:

The improvement of cell process and the combined effectiveness of anticancer drugs in preclinical research and development, as well as the development of immune cell cryopreservation technology and horizontal cooperation with domestic and foreign biotechnology factories to develop more innovative technologies

5. Qualification for screening (inclusion/exclusion criteria)：

Non AIDS and hepatitis B carriers

6. Expected benefits of the experiment:

Same as regular blood sampling

7. Participants should cooperate with:

Same as regular blood sampling

8. Test contact person and contact information:

Huang Yile 0932633137